Resource id #3DrugId:1d00000106resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   


Drug ID: 1d00000106

Drug Name: Anidulafungin

Generic Names: Eraxis

Category: Antifungals

Legal Status: Non Opioid Prescription only drug

OTC: No

Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: Candida infections- Loading Dose- The recommended dose is a single 200 on Day 1, followed by 100 mg daily dose thereafter.

Esophageal candidiasis- Loading Dose- The recommended dose is a single 100 mg on Day 1, followed by 50 mg daily dose thereafter.

Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms.

Recommended In: This medication is an antifungal agent, prescribed for candidemia and other forms of candida infections (intra-abdominal abscess and peritonitis) and esophageal candidiasis. It kills sensitive fungi. It kills sensitive fungi.

Directions For Use: It comes as a solution for injection to be administered by a healthcare provider into the vein.

Storage: Store unreconstituted vials, reconstituted solution, and diluted solution for infusion between 36 and 46F. Do not freeze. The reconstituted solution may be stored for up to 1 h; the diluted solution for infusion should be administered within 24 h.

Dosage Forms: Reconstituted powder for IV injection

Side Effects: Most Common - Rash, hives, flushing, itching, asthma, difficulty in breathing, and low blood pressure.

Blood - Decrease in platelets.

Heart - Heart block, abnormal heart rhythm, high and low blood pressure and flushing.

Eye - Eye pain, vision blurred and visual disturbances.

Gastrointestinal - Abdominal pain upper, constipation, diarrhea, indigestion, fecal incontinence, nausea and vomiting.

General - Infusion related reaction, swelling in the extremities and rigors.

Liver - Abnormal liver function tests and liver damage.

Metabolic - Increase in blood minerals.

Musculoskeletal - Back pain.

Central Nervous System - Convulsion, dizziness, and headache.

Respiratory - Cough.

Skin - Redness and increased sweating.

In Case of Overdose: No clinical adverse events were reported. Anidulafungin is not dialyzable.

Avoid If: Caution should be exercised in patients with history of liver impairment, children, bronchospasm, during pregnancy and breastfeeding.

Antifungal therapy should continue for at least 14 days after the last positive culture.

Drug Interaction: No significant interactions are observed yet.



Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main